5,6-Dihydro-4H-thieno[2,3-b]thiopyran | 33892-71-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran
• CAS: 33892-71-6
• 化学式: C₇H₈S₂
• 分子量: 156.3
• InChiKey: HNFBMBALGMVYMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6-Dihydro-4H-thieno[2,3-b]thiopyran 以25%的产率得到
  参考文献：
  名称：

  ANISIMOV A. V.; KULIKOV V. A.; VIKTOROVA E. A., BECTH. MGU. XIMIYA, 1979, 20, HO 4, 376-377

  摘要：

  DOI：
• 作为产物：
  描述：

  3-allylthiophene-2-thiol 生成 5,6-Dihydro-4H-thieno[2,3-b]thiopyran
  参考文献：
  名称：

  ANISIMOV A. V.; IONOVA V. F.; BABAJTSEV V. S.; GOVOREK V. K.; VIKTOROVA E+, XIMIYA GETEROTSIKL. SOEDIN., 1979, HO 8, 1062-1065

  摘要：

  DOI：

文献信息

• Heterocyclyl-substituted benzoylcyclohexandiones, their preparation, and their use as herbicides
  申请人：——

  公开号：US20020173424A1

  公开（公告）日：2002-11-21

  There are described benzoylcyclohexanediones of the formula I, their preparation, and their use as herbicides and plant growth regulators. 1 In this formula (I), R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R a , R b and R c are various radicals, and Y and Z are a monoatomic bridge element.

  该公式描述了式I的苯甲酰环己二酮，它们的制备以及它们作为除草剂和植物生长调节剂的用途。 在这个公式（I）中，R1，R2，R3，R4，R5，R6，R7，Ra，Rb和Rc是各种基团，Y和Z是单原子桥元素。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20030023098A1

  公开（公告）日：2003-01-30

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有减少心血管或镇静副作用。还包括制备和使用这些化合物的方法。
• [EN] (--)- HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] PROCÉDÉS DE FABRICATION DE (-) HUPERZINE A, COMPOSITIONS ASSOCIÉES, ET MÉTHODES DE TRAITEMENT
  申请人：UNIV YALE

  公开号：WO2012121863A1

  公开（公告）日：2012-09-13

  The invention provides (1) processes for making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; (2) compositions useful in making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives.

  该发明提供了三个方面：(1) 制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物的过程；(2) 用于制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物的组合物；以及(3) 使用几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物治疗或预防神经系统疾病的方法。
• Rab7 GTPase Inhibitors and Related Methods of Treatment
  申请人：Wandinger-Ness Angela

  公开号：US20140248268A1

  公开（公告）日：2014-09-04

  This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.

  本发明涉及化合物及其作为Rab7 GTP酶抑制剂或激活剂的用途，以治疗或预防Rab 7 GTP酶相关疾病，如神经病变、癌症、骨代谢疾病和脂质储存病。该发明还适用于Rab7被失活或其蛋白质-蛋白质相互作用被调节以促进病原体的细胞内生存的感染性疾病。所述化合物作为核苷酸结合的竞争性抑制剂，并且也具有作为靶向其他小GTP酶的支架的效用。在一个方面，本发明的治疗方法用于治疗或预防遗传性感觉神经病变，如Charcot-Marie-Tooth 2B病。还提供相关的制药组合物、测定和药物筛选。